<html>
  <head>
    <title></title>
    <!-- Licensed to: The Ideal Connection
         Document created using EDGARfilings PROfile 6.3.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: center;">UNITED STATES</div>
  <div style="text-align: center;">SECURITIES AND EXCHANGE COMMISSION</div>
  <div style="text-align: center;">WASHINGTON, DC 20549</div>
  <div><br>
  </div>
  <div style="text-align: center;">FORM 8-K</div>
  <div><br>
  </div>
  <div style="text-align: center;">CURRENT REPORT PURSUANT</div>
  <div style="text-align: center;">TO SECTION 13 OR 15(D) OF THE</div>
  <div style="text-align: center;">SECURITIES EXCHANGE ACT OF 1934</div>
  <div><br>
  </div>
  <div style="text-align: center;">Date of Report (Date of earliest event reported): November 30, 2019</div>
  <div style="text-align: center;"> <br>
  </div>
  <div style="text-align: center; font-weight: bold;"><u>QRONS INC.</u></div>
  <div style="text-align: center;">(Exact name of registrant as specified in its charter)</div>
  <div><br>
  </div>
  <div style="text-align: center;"><u>Wyoming</u></div>
  <div style="text-align: center;">(State or other jurisdiction of incorporation)</div>
  <div><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8e9a28f183e34764b557b34b9bd28295">

      <tr>
        <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
          <div style="text-align: center;">000-55800</div>
          <div style="text-align: center;">(Commission File Number)</div>
        </td>
        <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
          <div style="text-align: center;">81-3623646</div>
          <div style="text-align: center;">(IRS Employer Identification No.)</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="text-align: center;"><u>50 Battery Place, #7T, New York, New York10280</u></div>
  <div style="text-align: center;">&#160;(Address of principal executive offices) (Zip Code)</div>
  <div style="text-align: center;"><u> <br>
    </u></div>
  <div style="text-align: center;"><u>(212)-945-2080</u></div>
  <div style="text-align: center;">(Registrant's telephone number, including area code)</div>
  <div><br>
  </div>
  <div style="text-align: center;">___________________________________________</div>
  <div style="text-align: center;">&#160;(Former Name or Former Address, if Changed Since Last Report)</div>
  <div><br>
  </div>
  <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>
  <div><br>
  </div>
  <div style="text-align: justify;">|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
  <div><br>
  </div>
  <div style="text-align: justify;">|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
  <div><br>
  </div>
  <div style="text-align: justify;">|_|&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
  <div><br>
  </div>
  <div style="text-align: justify;">|_|&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div style="background-color: #FFFFFF;">
    <div>Securities registered pursuant to Section 12(b) of the Act: None</div>
    <div><br>
    </div>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z70e3c9e8732243a4b8d3bfc721e741ed">

      <tr>
        <td style="width: 33.59%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-size: 8pt; font-weight: bold;">Title of each class</div>
        </td>
        <td style="width: 1.4%; vertical-align: bottom;">
          <div style="font-size: 8pt;">&#160;</div>
        </td>
        <td style="width: 19.1%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-size: 8pt; font-weight: bold;">Trading</div>
          <div style="text-align: center; font-size: 8pt; font-weight: bold;">Symbol(s)</div>
        </td>
        <td style="width: 1.4%; vertical-align: bottom;">
          <div style="font-size: 8pt;">&#160;</div>
        </td>
        <td style="width: 44.51%; vertical-align: bottom; border-bottom: #000000 2px solid;">
          <div style="text-align: center; font-size: 8pt; font-weight: bold;">Name of each exchange</div>
          <div style="text-align: center; font-size: 8pt; font-weight: bold;">on which registered</div>
        </td>
      </tr>
      <tr>
        <td style="width: 33.59%; vertical-align: top;">
          <div style="text-align: center;">None</div>
        </td>
        <td style="width: 1.4%; vertical-align: bottom;">
          <div>&#160;</div>
        </td>
        <td style="width: 19.1%; vertical-align: top;">
          <div style="text-align: center;">N/A</div>
        </td>
        <td style="width: 1.4%; vertical-align: bottom;">
          <div>&#160;</div>
        </td>
        <td style="width: 44.51%; vertical-align: top;">
          <div style="text-align: center;">N/A</div>
        </td>
      </tr>

  </table>
  <div style="background-color: #FFFFFF;">
    <div><br>
    </div>
  </div>
  <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
  <div> <br>
  </div>
  <div style="text-indent: 36pt; margin-left: 252pt; margin-bottom: 5.25pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Emerging growth company </font><font style="font-size: 10pt;">[X]</font></div>
  <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
    Act. [&#160; ]</div>
  <div style="margin-bottom: 5.25pt;"><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
    <div style="page-break-after:always;" id="DSPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; font-weight: bold;">Section 1-Registrant&#8217;s Business and Operations</div>
  <div style="text-align: justify; font-weight: bold;">Item 1.01 Entry into a Material Definitive Agreement</div>
  <div><br>
  </div>
  <div style="text-align: justify;">On November 30, 2019, Qrons Inc. (the &#8220;Company&#8221;) entered into a royalty and license fee sharing agreement (the &#8220;Royalty Agreement&#8221;) with Ariel Scientific Innovations Ltd., an Israeli corporation (&#8220;Ariel&#8221;) which, among
    other things, supersedes and terminates the license and research funding agreement, dated December 14, 2016, as amended (the &#8220;License Agreement&#8221;), between the parties. Certain services agreements related to laboratory access and other services are not
    affected by such termination.</div>
  <div><br>
  </div>
  <div style="text-align: justify;">From and after the occurrence of an Exit Event, as such term is described in the Royalty Agreement, including an underwritten public offering of the Company&#8217;s shares with proceeds of at least $25 million, a
    consolidation, merger or reorganization of the Company, and a sale of all or substantially all of the shares and/or the assets of the Company, Ariel has the right to require the Company to issue&#160; up to 3% of the issued and outstanding shares of common
    stock of the Company at the time Ariel exercises such right.</div>
  <div><br>
  </div>
  <div style="text-align: justify;">In consideration for the parties&#8217; agreement to terminate the License Agreement and for future general scientific collaboration between the parties, the Company agreed to pay Ariel&#160; a royalty of 1.25% of net sales (as
    defined in the Royalty Agreement) of products sold by the Company, or its affiliates and licensees for fifteen years from the first commercial sale in a particular country.</div>
  <div><br>
  </div>
  <div style="text-align: justify;">The foregoing description of the Royalty Agreement is qualified in its entirety by reference to the full text of such Agreement, a copy of which is attached hereto as Exhibit 10.25 and is incorporated herein in its
    entirety by reference.</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-weight: bold;">Section 5 &#8211; Corporate Governance and Management</div>
  <div style="text-align: justify; font-weight: bold;">Item 5.02 Departure of Directors or Certain Officers</div>
  <div><br>
  </div>
  <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Dr. John N. Bonfiglio was terminated as Chief Operating Officer of the Company as of November 30, 2019.</div>
  <div><br>
  </div>
  <div style="font-weight: bold;">Section 9 &#8211; Financial Statements and Exhibits</div>
  <div style="font-weight: bold;">Item 9.01.&#160; Financial Statements and Exhibits</div>
  <div><br>
  </div>
  <div style="text-align: justify;">(d)&#160;&#160; Exhibits.</div>
  <div><br>
  </div>
  <div style="text-align: justify;"><u>Exhibit No</u>.<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> </font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><u>Description</u></div>
  <div><br>
  </div>
  <div style="text-align: justify;">
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3d3f6c2331d4a7dad10060e93edb6a7">

          <tr>
            <td style="width: 72pt; vertical-align: top; align: right;">10.25</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Royalty and License Fee Sharing Agreement, dated November 30, 2019, between the Company and Ariel Scientific Innovations Ltd.</div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
  </div>
  <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
  <div style="text-align: justify; text-indent: 36pt;"> <br>
  </div>
  <div style="text-align: justify; text-indent: 36pt;">
    <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

        <tr>
          <td valign="top" style="width: 50%;">&#160;</td>
          <td valign="top" colspan="2" style="width: 38%;"><strong></strong>QRONS INC.</td>
          <td valign="top" style="width: 12%;">&#160;</td>
        </tr>
        <tr>
          <td valign="top" style="width: 50%;">&#160;</td>
          <td valign="top" style="width: 3%;">&#160;</td>
          <td valign="top" style="width: 35%;">&#160;</td>
          <td valign="top" style="width: 12%;">&#160;</td>
        </tr>
        <tr>
          <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
            <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;">Date: December 3, 2019<br>
            </div>
          </td>
          <td valign="top" style="width: 3%; padding-bottom: 2px;">
            <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;">By: </div>
          </td>
          <td valign="top" align="left" style="width: 35%; border-bottom: 2px solid rgb(0, 0, 0); font-style: italic;">/s/Jonah Meer</td>
          <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="top" style="width: 50%;">&#160;</td>
          <td valign="top" style="width: 3%;">&#160;</td>
          <td valign="bottom" align="left" style="width: 35%;">Name: Jonah Meer</td>
          <td valign="top" style="width: 12%;">&#160;</td>
        </tr>
        <tr>
          <td valign="top" style="width: 50%;">&#160;</td>
          <td valign="top" style="width: 3%;">&#160;</td>
          <td valign="top" style="width: 35%;">Title: Chief Executive Officer <br>
          </td>
          <td valign="top" style="width: 12%;">&#160;</td>
        </tr>
        <tr>
          <td valign="top" style="width: 50%;">&#160;</td>
          <td valign="top" style="width: 3%;">&#160;</td>
          <td valign="top" style="width: 35%;">&#160;</td>
          <td valign="top" style="width: 12%;">&#160;</td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <br>
  <div><br>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k.htm", "description": "8-K", "secsgml_size_bytes": 15457}]
{"company-data": {"conformed-name": "Qrons Inc.", "cik": "0001689084", "assigned-sic": "2836", "irs-number": "813623646", "state-of-incorporation": "WY", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-55800", "film-number": "191265037"}, "business-address": {"street1": "50 BATTERY PLACE, #7T", "city": "NEW YORK", "state": "NY", "zip": "10280", "phone": "212-945-2080"}, "mail-address": {"street1": "50 BATTERY PLACE, #7T", "city": "NEW YORK", "state": "NY", "zip": "10280"}, "former-company": {"former-conformed-name": "BIOLABMART INC.", "date-changed": "20161102"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 30, 2019
QRONS INC.
(Exact name of registrant as specified in its charter)
Wyoming
(State or other jurisdiction of incorporation)
000-55800
(Commission File Number)
81-3623646
(IRS Employer Identification No.)
50 Battery Place, #7T, New York, New York10280
(Address of principal executive offices) (Zip Code)
(212)-945-2080
(Registrant's telephone number, including area code)
___________________________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Securities registered pursuant to Section 12(b) of the Act: None
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
None
N/A
N/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
[X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
    Act. [  ]
2
Section 1-Registrant's Business and Operations
Item 1.01 Entry into a Material Definitive Agreement
On November 30, 2019, Qrons Inc. (the "Company") entered into a royalty and license fee sharing agreement (the "Royalty Agreement") with Ariel Scientific Innovations Ltd., an Israeli corporation ("Ariel") which, among
    other things, supersedes and terminates the license and research funding agreement, dated December 14, 2016, as amended (the "License Agreement"), between the parties. Certain services agreements related to laboratory access and other services are not
    affected by such termination.
From and after the occurrence of an Exit Event, as such term is described in the Royalty Agreement, including an underwritten public offering of the Company's shares with proceeds of at least $25 million, a
    consolidation, merger or reorganization of the Company, and a sale of all or substantially all of the shares and/or the assets of the Company, Ariel has the right to require the Company to issue  up to 3% of the issued and outstanding shares of common
    stock of the Company at the time Ariel exercises such right.
In consideration for the parties' agreement to terminate the License Agreement and for future general scientific collaboration between the parties, the Company agreed to pay Ariel  a royalty of 1.25% of net sales (as
    defined in the Royalty Agreement) of products sold by the Company, or its affiliates and licensees for fifteen years from the first commercial sale in a particular country.
The foregoing description of the Royalty Agreement is qualified in its entirety by reference to the full text of such Agreement, a copy of which is attached hereto as Exhibit 10.25 and is incorporated herein in its
    entirety by reference.
Section 5 – Corporate Governance and Management
Item 5.02 Departure of Directors or Certain Officers
Dr. John N. Bonfiglio was terminated as Chief Operating Officer of the Company as of November 30, 2019.
Section 9 – Financial Statements and Exhibits
Item 9.01.  Financial Statements and Exhibits
(d)   Exhibits.
Exhibit No
.
Description
10.25
Royalty and License Fee Sharing Agreement, dated November 30, 2019, between the Company and Ariel Scientific Innovations Ltd.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
QRONS INC.
Date: December 3, 2019
By:
/s/Jonah Meer
Name: Jonah Meer
Title: Chief Executive Officer
4